Clinical Trials

Inclusion Criteria

• Diagnosis of T1D or T2D in the past 90 days made by a clinician (per medical record of new elevated A1C, diabetes specific medications and/or new diagnosis of diabetes).
• Diabetes not related to ongoing steroid use, or pancreatic insufficiency from cancer, cystic fibrosis, or other infiltrating disease (per patient report).
• COVID+ defined as a documented case of SARS-CoV-2 infection (with positive SARS-CoV-2 by PCR or rapid antigen, including home tests or prescriptions/dispensing for paxlovid, remdesivir, molnupiravir, or a monoclonal antibody used for treatment) in 365 days prior to diagnosis (ideally within 180 days) of diabetes diagnosis OR COVIDdefined as no known history of COVID-19 and no use of a COVID-19 treatment in the past 365 days).
• Willing to participate for 2 years.
• English or Spanish speaking.
• Age 11 years and older.

 (Patients who report COVID- status will also have SARS-CoV-2 nucleocapsid antibody tests performed at enrollment and results will be batched and analyzed as part of the study).

Exclusion Criteria

• Life expectancy less than 2 years.
• Insulinoma.
• Active pregnancy at enrollment or within 6 months of enrollment.
• Sickle cell anemia or other hemoglobinopathy.
• Dialysis dependence (for Extensive Level engagement).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/08/2024. Questions regarding updates should be directed to the study team contact.